{"ticker": {"uuid": "5ce4b443-30a8-4ff2-b7bb-8cbeaa864311", "symbol": "INDP", "name": "Indaptus Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZmd0cXItRlItNjVwcTByX1hYRU5mWkE4M0lHSTdqblRDX3dLWVVQQWpBbTFUWHpTOTFxeXByZXFpZ3BpMmFWNzNDNkNOeElZVFhXbXRDSkdEWG55djBCUXBGcGZPcU93NUttZmFZUXdFVXhqMF9jMnByal9JaUZBVDQ3amVJbHJTRkRBT091VkRzWS1CX3hhbi1xYnQ1eHFlTnpZbHJmVlc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T12:03:46+00:00", "published_display": "20 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) Proxy filing Summary", "summary": "Indaptus Therapeutics (INDP) has scheduled its Annual Meeting for August 10, 2026, to be held virtually. Key proposals include the election of Class II directors, ratification of Haskell & White LLP as independent auditor, and approval of a new equity incentive plan, all recommen", "url": "https://quartr.com/events/indaptus-therapeutics-inc-indp-proxy-filing_F161gnoE", "source_name": "Quartr", "published_at": "2026-07-16T20:11:28", "published_display": "16 Jul 2026 20:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan", "summary": "Indaptus Therapeutics (NASDAQ: INDP) is seeking shareholder approval for its 2026 Equity Incentive Plan at the upcoming annual meeting on August 10, 2026. The plan will initially reserve 13,324,232 shares and includes an annual automatic increase of 5% of outstanding shares from ", "url": "https://www.stocktitan.net/sec-filings/INDP/def-14a-indaptus-therapeutics-inc-definitive-proxy-statement-8147618384a1.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:10:05", "published_display": "16 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Indaptus Therapeutics (Nasdaq:INDP) - Stock Analysis", "summary": "This article provides a detailed stock analysis of Indaptus Therapeutics (INDP), a clinical biotechnology company developing anti-cancer and anti-viral immunotherapy products. It highlights significant risks such as shareholder dilution, declining earnings, and a short cash runwa", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-09T17:09:27", "published_display": "09 Jul 2026 17:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$34k As Indaptus Therapeutics Drops", "summary": "Indaptus Therapeutics saw its stock price drop by 11%, leaving insiders, who had bought US$50.4k worth of shares at an average of US$8.30, with a current investment value of only US$16.2k. Despite this loss, the article notes that the single insider buyer, Jeffrey Meckler, purcha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics/news/insider-traders-lose-us34k-as-indaptus-therapeutics-drops", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:39:32", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) News Flow", "summary": "This article provides an analysis of recent news and stock performance for Indaptus Therapeutics (INDP). It highlights a significant trading volume increase and outlines upcoming clinical catalysts that could impact the stock. The author purchased shares and reiterates a long-ter", "url": "https://www.moomoo.com/stock/INDP-US/news?chain_id=Name1K9-3FXPhg.1kvafk0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A61,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Ffeed%2Ftoday-s-pre-market-movers-and-top-ratings-salesforce-okta-113594793263109%22%7D", "source_name": "Moomoo", "published_at": "2026-06-29T14:12:34", "published_display": "29 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 13D/A for Indaptus Therapeutics, dated June 26. The piece is notably brief, providing only the title, publication date, and a Reuters copyright image reference, along with a link to the company's stock symbol (INDP). ", "url": "https://za.investing.com/news/stock-market-news/form-13da-indaptus-therapeutics-for-26-june-93CH-4346620", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T12:41:44", "published_display": "27 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yun Yao (NASDAQ: INDP) reports 31.5% Indaptus stake change", "summary": "Yun Yao filed an Amendment No. 2 to her Schedule 13D for Indaptus Therapeutics, Inc. (INDP), reporting a 31.51% beneficial ownership stake, which is 41,991,000 shares. This decrease from her previous percentage is due to Indaptus's private placement of additional shares on June 1", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-92426c2e9bad.html", "source_name": "Stock Titan", "published_at": "2026-06-27T12:11:13", "published_display": "27 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com", "summary": "This article reports on the filing of Form S-3 by Indaptus Therapeutics Inc. on June 26. The brief announcement provides the company and date of the filing. It also includes market data and popular news headlines from Investing.com.", "url": "https://za.investing.com/news/stock-market-news/form-s3-indaptus-therapeutics-inc-for-26-june-93CH-4346470", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T12:11:13", "published_display": "27 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares", "summary": "Sino Lion Ventures Limited and Chenhao Xu have filed an amended Schedule 13D for Indaptus Therapeutics, Inc., reporting beneficial ownership of 38,895,000 shares, representing 29.19% of the company. Their percentage ownership decreased due to Indaptus's private placement on June ", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-9bec53301a12.html", "source_name": "Stock Titan", "published_at": "2026-06-27T02:39:42", "published_display": "27 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake", "summary": "Indaptus Therapeutics CEO Junyi Dai reported a beneficial ownership of 8.44% of the company's common stock, totaling 11,250,000 shares, as of June 24, 2026. This stake was acquired through the conversion of Series AA and Series AAA Preferred Stock, purchased for $1,156,642.43 usi", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-b9ae65923c9a.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:39:42", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance", "summary": "Indaptus Therapeutics investor Ting Yang's ownership stake has decreased to 8.44% of the outstanding shares, totaling 11,250,000 shares, as of June 24, 2026. This reduction, a drop of more than 1%, is attributed to a private placement completed by Indaptus on June 17, 2026, which", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-ef480e7d298a.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:39:42", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused", "summary": "Indaptus Therapeutics (INDP) has registered 18.864 million shares for resale by selling stockholders, converted from Series AA and AAA preferred stock. The company will not receive any proceeds from these resales. Additionally, Indaptus has paused the clinical development of its ", "url": "https://www.stocktitan.net/sec-filings/INDP/s-3-indaptus-therapeutics-inc-shelf-registration-statement-1c0fde9469fa.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:10:26", "published_display": "26 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics - To Issue 20 Million Shares At $0.6 Per Share - SEC Filing", "summary": "Indaptus Therapeutics announced its intention to issue 20 million shares at a price of $0.6 per share, as revealed in a recent SEC filing. The information was initially reported by Reuters and is now available through TradingView News. This financial move marks a notable developm", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42W07S:0-indaptus-therapeutics-to-issue-20-million-shares-at-0-6-per-share-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-25T22:41:24", "published_display": "25 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revenue per share of Indaptus Therapeutics, Inc. \u2013 NASDAQ:INDP", "summary": "This article provides financial information for Indaptus Therapeutics, Inc. (NASDAQ: INDP), specifically focusing on its revenue per share. The content appears to be a stub or a data point from a financial platform, indicating a period value, change, and change percentage.", "url": "https://www.tradingview.com/symbols/NASDAQ-INDP/financials-statistics-and-ratios/revenue-per-share/", "source_name": "TradingView", "published_at": "2026-06-25T21:09:45", "published_display": "25 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDAPTUS THERAPEUTICS - TO ISSUE 20 MLN SHARES AT $0.6 PER SHARE - SEC FILING", "summary": "Indaptus Therapeutics plans to issue 20 million shares at a price of $0.6 per share. This information was disclosed in a recent SEC filing. The offering aims to raise capital for the company.", "url": "https://www.moomoo.com/news/flash/22695433/indaptus-therapeutics-to-issue-20-mln-shares-at-0-6", "source_name": "Moomoo", "published_at": "2026-06-25T11:10:10", "published_display": "25 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Raises $12 Million in Offshore Private Placement at $0.60 Per Share", "summary": "Indaptus Therapeutics has successfully raised approximately $12 million through an offshore private placement, selling 20,000,000 common shares at $0.60 per share to non-U.S. accredited investors. This offering represented less than 20% of outstanding shares and involved no commi", "url": "https://www.tradingview.com/news/tradingview:eb5c816daf6b4:0-indaptus-therapeutics-raises-12-million-in-offshore-private-placement-at-0-60-per-share/", "source_name": "TradingView", "published_at": "2026-06-24T19:40:00", "published_display": "24 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placement", "summary": "Indaptus Therapeutics (INDP) announced a Regulation S private placement, selling 20 million common shares at $0.60 each to non-U.S. accredited investors, raising approximately $12 million in gross proceeds. This transaction represents less than 20% dilution of outstanding shares ", "url": "https://www.stocktitan.net/sec-filings/INDP/8-k-indaptus-therapeutics-inc-reports-material-event-2905a9f83ebd.html", "source_name": "Stock Titan", "published_at": "2026-06-24T19:40:00", "published_display": "24 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) asks shareholders to approve $300M PIPE, equity plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxObzhPbWNiZGNOVzdRNzFsYV9iM2FaX2RST0p1S3R1c0JicDVSR3ZUdFNOZ0J5OWdyYl81d1plYU05YThfbl9KVmZUTVlSLUFZQVcybS0xdThfNTZGTnIwS1pmaXBpbnp2OGlVcmptMnNUNElkdFp3LThxX1VxZURXMFNxcjJDLTM5anZpZm1ldHA3cmJRMXhMWDRFdW10M0FYWGk1dlI2Y0NyNXR1dG5TdXMzNHRnZzhuT0FCMHVnMXk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Inc (INDP) Institutional Confidence", "summary": "The article provides an overview of Indaptus Therapeutics Inc (INDP)'s institutional confidence, highlighting its TradingKey Stock Score and shareholder activity. It lists significant individual and institutional shareholders, including changes in their holdings. The company's st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Indaptus Therapeutics Inc (INDP), noting that no earnings forecast score is currently available, contrasting with the biotechnology industry average. Analysts predict a price target of $10.00 for INDP. The report also highlights past", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis", "summary": "Indaptus Therapeutics Inc (INDP) has a current valuation score of 6.58, placing it 321st out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.35, which is notably lower than its recent high and higher than its recent low. Key valuation metric", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders", "summary": "Abbott Cooper PLLC has announced an investigation into Indaptus Therapeutics, Inc. (Nasdaq: INDP) on behalf of stockholders who held shares prior to December 22, 2025. The investigation will determine if Indaptus's Board violated its fiduciary duties regarding a private placement", "url": "https://www.globenewswire.com/news-release/2026/06/18/3313904/0/en/abbott-cooper-pllc-announces-investigation-on-behalf-of-indaptus-therapeutics-inc-stockholders.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T02:40:45", "published_display": "18 Jun 2026 02:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change \u2013 Junyi Dai Appointed CEO", "summary": "Indaptus Therapeutics, Inc. filed an 8-K report detailing leadership changes, specifically referencing Item 5.02, which pertains to the departure or appointment of officers. The filing confirms the company is not an emerging growth company and does not indicate any major corporat", "url": "https://www.minichart.com.sg/2026/06/06/indaptus-therapeutics-inc-files-form-8-k-announcing-ceo-change-junyi-dai-appointed-ceo/", "source_name": "Minichart", "published_at": "2026-06-06T10:13:00", "published_display": "06 Jun 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit", "summary": "Indaptus Therapeutics (INDP) reported several leadership changes, including the resignations of directors David E. Lazar and Avraham Ben-Tzvi, effective June 5, 2026, and COO Walt A. Linscott, effective June 1, 2026. Linscott will transition to a strategic advisory consulting rol", "url": "https://www.stocktitan.net/sec-filings/INDP/8-k-indaptus-therapeutics-inc-reports-material-event-f2795d896f2e.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:39:51", "published_display": "05 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty", "summary": "Indaptus Therapeutics (INDP) stock jumped 53.8% on heavy volume following its reverse stock split. The company is exploring financing and strategic options, raising investor interest in potential future developments. This significant price movement highlights the market's respons", "url": "https://www.moomoo.com/news/post/71107031/indaptus-therapeutics-indp-jumps-53-8-amid-heavy-volume-as", "source_name": "Moomoo", "published_at": "2026-06-05T03:09:41", "published_display": "05 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDP - Indaptus Therapeutics Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Indaptus Therapeutics Inc (INDP) stock, including its latest price, financial metrics, insider ownership, and recent news. The article highlights the company's focus on developing novel anti-cancer and anti-viral immunotherapies, wit", "url": "https://finviz.com/stock?t=INDP", "source_name": "Finviz", "published_at": "2026-06-02T16:10:44", "published_display": "02 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock Surges - Weak Earnings Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMEdlVVQxZjAwOEhwOHYtZG1mYjdNc0VEa0k2R0VzaXlxcWQwTnVBRmsyZ004cFY1X3p4VGlDeTZOanpkaWtPQ0lhR2lMbl9uQ2wwY0FFNlZpY0VmOWg3SVZMM2pDZTRZbDJHNDl2MTVOR1hzMHZzQmlaU1hnamFQUUk1N1FTdWpKSk8yYXc5OVhRVnp3ZmxXRWNOZFBuV20tdHE0bTg0T19IRmgycEpaSlBKUzNiWTdId1pCMXgxMWk3LWYwZmlJbDNua1Q4Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Releases Q1 2026 Financial Results", "summary": "Indaptus Therapeutics, Inc. reported its Q1 2026 financial results, showing a significantly narrower loss of $0.23 per share, an improvement from $9.11 in the prior year. The clinical biotechnology company, trading as INDP, posted a net loss of $2.5M as it continues to advance it", "url": "https://news.alphastreet.com/indaptus-therapeutics-releases-q1-2026-financial-results/amp/", "source_name": "AlphaStreet", "published_at": "2026-05-16T07:10:21", "published_display": "16 May 2026 07:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway", "summary": "Indaptus Therapeutics (INDP) reported a Q1 2026 net loss of $2.54 million, an improvement from the previous year, largely due to a significant reduction in R&D spending as clinical activity was wound down. The company's cash and cash equivalents dwindled to $1.50 million, and it ", "url": "https://www.stocktitan.net/sec-filings/INDP/10-q-indaptus-therapeutics-inc-quarterly-earnings-report-46e185b8a515.html", "source_name": "Stock Titan", "published_at": "2026-05-16T06:39:03", "published_display": "16 May 2026 06:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing", "summary": "Indaptus Therapeutics, Inc. has reported a net loss of $2.54 million for Q1 2026 and an accumulated deficit of $83.83 million, leading to a substantial doubt about its ability to continue as a going concern. The company's stockholders' equity decreased significantly, and it antic", "url": "https://www.minichart.com.sg/2026/05/15/indaptus-therapeutics-inc-reports-substantial-doubt-about-going-concern-and-highlights-key-risks-in-q1-2026-10-q-filing/", "source_name": "Minichart", "published_at": "2026-05-16T05:39:39", "published_display": "16 May 2026 05:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/indaptus-therapeutics-reports-first-quarter-110000439.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:00:00+00:00", "published_display": "15 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics reassesses decoy platform as cash dwindles", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOTFhKWDU1cmdkclVkZTJaQkJzNmp4azl0RjdWOU5TQ1pJekpzcU5DbXdQSTNaUnhqVDVaZnJYYWtWajRCblpHZlg4SnBZdnVhMlgtMy1FZ2lkNWg2OHNrU3RUdGd2b3RLLUN1V3dIVEVNWFVER2FKMVNTM3RwUjBBeUFrLTE?oc=5", "source_name": "grafa.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Indaptus ends Q1 with $1.5M cash, weighs next steps", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYXlYRmlLRlJhWHhSUU9DNWo1U3lBV1BxcDV2Sk1ycFNIQUJ5VF9UNUdGTHUxVkEwS2k2QkJrMkRGclEzNkJGMnF2QlBtb01uZDljVUREYWxYTENwTFFpMVdjMld0bHF2RzdndU1nTktOUnV4dEFHX1Z5a09qYjlaZm5yVWlqRmM3bU5YdmVWOFV4UnRxcGtSNnVSSDZKaS1nMlV5R0RvTmh1VHZXV1REbTAxMHdqTzBTd1htWHFR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Yun Yao Leads Investor Group, Secures CEO Change at Indaptus Therapeutics, Inc. with 37.8% Stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPM0Z3VlFQYTMyOWJXZkR0RnhoOGZiNU1TWXZta1VWRUU3S3lJLVJab2oxUTNOUVhPaFJYOWdxTVFlZlNfX1M1Y01UQVhOZ0JxdHJpTGtLcGVDRTNqSC1TMU11T3pZWHpfcjdwc0d0LXJmUFVBQzV1WUpQQlNoOEdwR3IwazZJUV9nZ19xSUdGWEk2OUNKNU45X01YWmVLTFRaU0RiM0tmZXRSd3ZPS0xuVk45TW5ERkdVN04yU29xTzhab0MwMnFHTTkzZENHb1pIek9BLVRmUWtvT0VibEl6b2RnYWRaaXBPWGc?oc=5", "source_name": "TradingView", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Indaptus Therapeutics (INDP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9WQ3Y0djFNai11aTlQTlIzWm5TSEptT3RFX0NWaEMxcWYtVGFQN1JkaHliN2diMTQzWmxOQzJoUXlMVk1vTVE1blRXMUhsZDlOcnU1X01yeDRmUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-08-09T12:42:51+00:00", "published_display": "09 Aug 2021 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZmd0cXItRlItNjVwcTByX1hYRU5mWkE4M0lHSTdqblRDX3dLWVVQQWpBbTFUWHpTOTFxeXByZXFpZ3BpMmFWNzNDNkNOeElZVFhXbXRDSkdEWG55djBCUXBGcGZPcU93NUttZmFZUXdFVXhqMF9jMnByal9JaUZBVDQ3amVJbHJTRkRBT091VkRzWS1CX3hhbi1xYnQ1eHFlTnpZbHJmVlc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T12:03:46+00:00", "published_display": "20 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) Proxy filing Summary", "summary": "Indaptus Therapeutics (INDP) has scheduled its Annual Meeting for August 10, 2026, to be held virtually. Key proposals include the election of Class II directors, ratification of Haskell & White LLP as independent auditor, and approval of a new equity incentive plan, all recommen", "url": "https://quartr.com/events/indaptus-therapeutics-inc-indp-proxy-filing_F161gnoE", "source_name": "Quartr", "published_at": "2026-07-16T20:11:28", "published_display": "16 Jul 2026 20:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan", "summary": "Indaptus Therapeutics (NASDAQ: INDP) is seeking shareholder approval for its 2026 Equity Incentive Plan at the upcoming annual meeting on August 10, 2026. The plan will initially reserve 13,324,232 shares and includes an annual automatic increase of 5% of outstanding shares from ", "url": "https://www.stocktitan.net/sec-filings/INDP/def-14a-indaptus-therapeutics-inc-definitive-proxy-statement-8147618384a1.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:10:05", "published_display": "16 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (Nasdaq:INDP) - Stock Analysis", "summary": "This article provides a detailed stock analysis of Indaptus Therapeutics (INDP), a clinical biotechnology company developing anti-cancer and anti-viral immunotherapy products. It highlights significant risks such as shareholder dilution, declining earnings, and a short cash runwa", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-09T17:09:27", "published_display": "09 Jul 2026 17:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$34k As Indaptus Therapeutics Drops", "summary": "Indaptus Therapeutics saw its stock price drop by 11%, leaving insiders, who had bought US$50.4k worth of shares at an average of US$8.30, with a current investment value of only US$16.2k. Despite this loss, the article notes that the single insider buyer, Jeffrey Meckler, purcha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics/news/insider-traders-lose-us34k-as-indaptus-therapeutics-drops", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:39:32", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) News Flow", "summary": "This article provides an analysis of recent news and stock performance for Indaptus Therapeutics (INDP). It highlights a significant trading volume increase and outlines upcoming clinical catalysts that could impact the stock. The author purchased shares and reiterates a long-ter", "url": "https://www.moomoo.com/stock/INDP-US/news?chain_id=Name1K9-3FXPhg.1kvafk0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A61,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Ffeed%2Ftoday-s-pre-market-movers-and-top-ratings-salesforce-okta-113594793263109%22%7D", "source_name": "Moomoo", "published_at": "2026-06-29T14:12:34", "published_display": "29 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 13D/A for Indaptus Therapeutics, dated June 26. The piece is notably brief, providing only the title, publication date, and a Reuters copyright image reference, along with a link to the company's stock symbol (INDP). ", "url": "https://za.investing.com/news/stock-market-news/form-13da-indaptus-therapeutics-for-26-june-93CH-4346620", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T12:41:44", "published_display": "27 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yun Yao (NASDAQ: INDP) reports 31.5% Indaptus stake change", "summary": "Yun Yao filed an Amendment No. 2 to her Schedule 13D for Indaptus Therapeutics, Inc. (INDP), reporting a 31.51% beneficial ownership stake, which is 41,991,000 shares. This decrease from her previous percentage is due to Indaptus's private placement of additional shares on June 1", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-92426c2e9bad.html", "source_name": "Stock Titan", "published_at": "2026-06-27T12:11:13", "published_display": "27 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com", "summary": "This article reports on the filing of Form S-3 by Indaptus Therapeutics Inc. on June 26. The brief announcement provides the company and date of the filing. It also includes market data and popular news headlines from Investing.com.", "url": "https://za.investing.com/news/stock-market-news/form-s3-indaptus-therapeutics-inc-for-26-june-93CH-4346470", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T12:11:13", "published_display": "27 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares", "summary": "Sino Lion Ventures Limited and Chenhao Xu have filed an amended Schedule 13D for Indaptus Therapeutics, Inc., reporting beneficial ownership of 38,895,000 shares, representing 29.19% of the company. Their percentage ownership decreased due to Indaptus's private placement on June ", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-9bec53301a12.html", "source_name": "Stock Titan", "published_at": "2026-06-27T02:39:42", "published_display": "27 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake", "summary": "Indaptus Therapeutics CEO Junyi Dai reported a beneficial ownership of 8.44% of the company's common stock, totaling 11,250,000 shares, as of June 24, 2026. This stake was acquired through the conversion of Series AA and Series AAA Preferred Stock, purchased for $1,156,642.43 usi", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-b9ae65923c9a.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:39:42", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance", "summary": "Indaptus Therapeutics investor Ting Yang's ownership stake has decreased to 8.44% of the outstanding shares, totaling 11,250,000 shares, as of June 24, 2026. This reduction, a drop of more than 1%, is attributed to a private placement completed by Indaptus on June 17, 2026, which", "url": "https://www.stocktitan.net/sec-filings/INDP/schedule-13d-a-indaptus-therapeutics-inc-amended-major-shareholder-re-ef480e7d298a.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:39:42", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused", "summary": "Indaptus Therapeutics (INDP) has registered 18.864 million shares for resale by selling stockholders, converted from Series AA and AAA preferred stock. The company will not receive any proceeds from these resales. Additionally, Indaptus has paused the clinical development of its ", "url": "https://www.stocktitan.net/sec-filings/INDP/s-3-indaptus-therapeutics-inc-shelf-registration-statement-1c0fde9469fa.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:10:26", "published_display": "26 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics - To Issue 20 Million Shares At $0.6 Per Share - SEC Filing", "summary": "Indaptus Therapeutics announced its intention to issue 20 million shares at a price of $0.6 per share, as revealed in a recent SEC filing. The information was initially reported by Reuters and is now available through TradingView News. This financial move marks a notable developm", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42W07S:0-indaptus-therapeutics-to-issue-20-million-shares-at-0-6-per-share-sec-filing/", "source_name": "TradingView", "published_at": "2026-06-25T22:41:24", "published_display": "25 Jun 2026 22:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Revenue per share of Indaptus Therapeutics, Inc. \u2013 NASDAQ:INDP", "summary": "This article provides financial information for Indaptus Therapeutics, Inc. (NASDAQ: INDP), specifically focusing on its revenue per share. The content appears to be a stub or a data point from a financial platform, indicating a period value, change, and change percentage.", "url": "https://www.tradingview.com/symbols/NASDAQ-INDP/financials-statistics-and-ratios/revenue-per-share/", "source_name": "TradingView", "published_at": "2026-06-25T21:09:45", "published_display": "25 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDAPTUS THERAPEUTICS - TO ISSUE 20 MLN SHARES AT $0.6 PER SHARE - SEC FILING", "summary": "Indaptus Therapeutics plans to issue 20 million shares at a price of $0.6 per share. This information was disclosed in a recent SEC filing. The offering aims to raise capital for the company.", "url": "https://www.moomoo.com/news/flash/22695433/indaptus-therapeutics-to-issue-20-mln-shares-at-0-6", "source_name": "Moomoo", "published_at": "2026-06-25T11:10:10", "published_display": "25 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Raises $12 Million in Offshore Private Placement at $0.60 Per Share", "summary": "Indaptus Therapeutics has successfully raised approximately $12 million through an offshore private placement, selling 20,000,000 common shares at $0.60 per share to non-U.S. accredited investors. This offering represented less than 20% of outstanding shares and involved no commi", "url": "https://www.tradingview.com/news/tradingview:eb5c816daf6b4:0-indaptus-therapeutics-raises-12-million-in-offshore-private-placement-at-0-60-per-share/", "source_name": "TradingView", "published_at": "2026-06-24T19:40:00", "published_display": "24 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placement", "summary": "Indaptus Therapeutics (INDP) announced a Regulation S private placement, selling 20 million common shares at $0.60 each to non-U.S. accredited investors, raising approximately $12 million in gross proceeds. This transaction represents less than 20% dilution of outstanding shares ", "url": "https://www.stocktitan.net/sec-filings/INDP/8-k-indaptus-therapeutics-inc-reports-material-event-2905a9f83ebd.html", "source_name": "Stock Titan", "published_at": "2026-06-24T19:40:00", "published_display": "24 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) asks shareholders to approve $300M PIPE, equity plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxObzhPbWNiZGNOVzdRNzFsYV9iM2FaX2RST0p1S3R1c0JicDVSR3ZUdFNOZ0J5OWdyYl81d1plYU05YThfbl9KVmZUTVlSLUFZQVcybS0xdThfNTZGTnIwS1pmaXBpbnp2OGlVcmptMnNUNElkdFp3LThxX1VxZURXMFNxcjJDLTM5anZpZm1ldHA3cmJRMXhMWDRFdW10M0FYWGk1dlI2Y0NyNXR1dG5TdXMzNHRnZzhuT0FCMHVnMXk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Inc (INDP) Institutional Confidence", "summary": "The article provides an overview of Indaptus Therapeutics Inc (INDP)'s institutional confidence, highlighting its TradingKey Stock Score and shareholder activity. It lists significant individual and institutional shareholders, including changes in their holdings. The company's st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Indaptus Therapeutics Inc (INDP), noting that no earnings forecast score is currently available, contrasting with the biotechnology industry average. Analysts predict a price target of $10.00 for INDP. The report also highlights past", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indp/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis", "summary": "Indaptus Therapeutics Inc (INDP) has a current valuation score of 6.58, placing it 321st out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.35, which is notably lower than its recent high and higher than its recent low. Key valuation metric", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-indp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders", "summary": "Abbott Cooper PLLC has announced an investigation into Indaptus Therapeutics, Inc. (Nasdaq: INDP) on behalf of stockholders who held shares prior to December 22, 2025. The investigation will determine if Indaptus's Board violated its fiduciary duties regarding a private placement", "url": "https://www.globenewswire.com/news-release/2026/06/18/3313904/0/en/abbott-cooper-pllc-announces-investigation-on-behalf-of-indaptus-therapeutics-inc-stockholders.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T02:40:45", "published_display": "18 Jun 2026 02:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change \u2013 Junyi Dai Appointed CEO", "summary": "Indaptus Therapeutics, Inc. filed an 8-K report detailing leadership changes, specifically referencing Item 5.02, which pertains to the departure or appointment of officers. The filing confirms the company is not an emerging growth company and does not indicate any major corporat", "url": "https://www.minichart.com.sg/2026/06/06/indaptus-therapeutics-inc-files-form-8-k-announcing-ceo-change-junyi-dai-appointed-ceo/", "source_name": "Minichart", "published_at": "2026-06-06T10:13:00", "published_display": "06 Jun 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit", "summary": "Indaptus Therapeutics (INDP) reported several leadership changes, including the resignations of directors David E. Lazar and Avraham Ben-Tzvi, effective June 5, 2026, and COO Walt A. Linscott, effective June 1, 2026. Linscott will transition to a strategic advisory consulting rol", "url": "https://www.stocktitan.net/sec-filings/INDP/8-k-indaptus-therapeutics-inc-reports-material-event-f2795d896f2e.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:39:51", "published_display": "05 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty", "summary": "Indaptus Therapeutics (INDP) stock jumped 53.8% on heavy volume following its reverse stock split. The company is exploring financing and strategic options, raising investor interest in potential future developments. This significant price movement highlights the market's respons", "url": "https://www.moomoo.com/news/post/71107031/indaptus-therapeutics-indp-jumps-53-8-amid-heavy-volume-as", "source_name": "Moomoo", "published_at": "2026-06-05T03:09:41", "published_display": "05 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INDP - Indaptus Therapeutics Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Indaptus Therapeutics Inc (INDP) stock, including its latest price, financial metrics, insider ownership, and recent news. The article highlights the company's focus on developing novel anti-cancer and anti-viral immunotherapies, wit", "url": "https://finviz.com/stock?t=INDP", "source_name": "Finviz", "published_at": "2026-06-02T16:10:44", "published_display": "02 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock Surges - Weak Earnings Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMEdlVVQxZjAwOEhwOHYtZG1mYjdNc0VEa0k2R0VzaXlxcWQwTnVBRmsyZ004cFY1X3p4VGlDeTZOanpkaWtPQ0lhR2lMbl9uQ2wwY0FFNlZpY0VmOWg3SVZMM2pDZTRZbDJHNDl2MTVOR1hzMHZzQmlaU1hnamFQUUk1N1FTdWpKSk8yYXc5OVhRVnp3ZmxXRWNOZFBuV20tdHE0bTg0T19IRmgycEpaSlBKUzNiWTdId1pCMXgxMWk3LWYwZmlJbDNua1Q4Zw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 15, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Releases Q1 2026 Financial Results", "summary": "Indaptus Therapeutics, Inc. reported its Q1 2026 financial results, showing a significantly narrower loss of $0.23 per share, an improvement from $9.11 in the prior year. The clinical biotechnology company, trading as INDP, posted a net loss of $2.5M as it continues to advance it", "url": "https://news.alphastreet.com/indaptus-therapeutics-releases-q1-2026-financial-results/amp/", "source_name": "AlphaStreet", "published_at": "2026-05-16T07:10:21", "published_display": "16 May 2026 07:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway", "summary": "Indaptus Therapeutics (INDP) reported a Q1 2026 net loss of $2.54 million, an improvement from the previous year, largely due to a significant reduction in R&D spending as clinical activity was wound down. The company's cash and cash equivalents dwindled to $1.50 million, and it ", "url": "https://www.stocktitan.net/sec-filings/INDP/10-q-indaptus-therapeutics-inc-quarterly-earnings-report-46e185b8a515.html", "source_name": "Stock Titan", "published_at": "2026-05-16T06:39:03", "published_display": "16 May 2026 06:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing", "summary": "Indaptus Therapeutics, Inc. has reported a net loss of $2.54 million for Q1 2026 and an accumulated deficit of $83.83 million, leading to a substantial doubt about its ability to continue as a going concern. The company's stockholders' equity decreased significantly, and it antic", "url": "https://www.minichart.com.sg/2026/05/15/indaptus-therapeutics-inc-reports-substantial-doubt-about-going-concern-and-highlights-key-risks-in-q1-2026-10-q-filing/", "source_name": "Minichart", "published_at": "2026-05-16T05:39:39", "published_display": "16 May 2026 05:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/indaptus-therapeutics-reports-first-quarter-110000439.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:00:00+00:00", "published_display": "15 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics reassesses decoy platform as cash dwindles", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOTFhKWDU1cmdkclVkZTJaQkJzNmp4azl0RjdWOU5TQ1pJekpzcU5DbXdQSTNaUnhqVDVaZnJYYWtWajRCblpHZlg4SnBZdnVhMlgtMy1FZ2lkNWg2OHNrU3RUdGd2b3RLLUN1V3dIVEVNWFVER2FKMVNTM3RwUjBBeUFrLTE?oc=5", "source_name": "grafa.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Indaptus ends Q1 with $1.5M cash, weighs next steps", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYXlYRmlLRlJhWHhSUU9DNWo1U3lBV1BxcDV2Sk1ycFNIQUJ5VF9UNUdGTHUxVkEwS2k2QkJrMkRGclEzNkJGMnF2QlBtb01uZDljVUREYWxYTENwTFFpMVdjMld0bHF2RzdndU1nTktOUnV4dEFHX1Z5a09qYjlaZm5yVWlqRmM3bU5YdmVWOFV4UnRxcGtSNnVSSDZKaS1nMlV5R0RvTmh1VHZXV1REbTAxMHdqTzBTd1htWHFR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yun Yao Leads Investor Group, Secures CEO Change at Indaptus Therapeutics, Inc. with 37.8% Stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPM0Z3VlFQYTMyOWJXZkR0RnhoOGZiNU1TWXZta1VWRUU3S3lJLVJab2oxUTNOUVhPaFJYOWdxTVFlZlNfX1M1Y01UQVhOZ0JxdHJpTGtLcGVDRTNqSC1TMU11T3pZWHpfcjdwc0d0LXJmUFVBQzV1WUpQQlNoOEdwR3IwazZJUV9nZ19xSUdGWEk2OUNKNU45X01YWmVLTFRaU0RiM0tmZXRSd3ZPS0xuVk45TW5ERkdVN04yU29xTzhab0MwMnFHTTkzZENHb1pIek9BLVRmUWtvT0VibEl6b2RnYWRaaXBPWGc?oc=5", "source_name": "TradingView", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Indaptus Therapeutics (INDP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9WQ3Y0djFNai11aTlQTlIzWm5TSEptT3RFX0NWaEMxcWYtVGFQN1JkaHliN2diMTQzWmxOQzJoUXlMVk1vTVE1blRXMUhsZDlOcnU1X01yeDRmUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-08-09T12:42:51+00:00", "published_display": "09 Aug 2021 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 45, "sentiment_summary": {"positive": 7, "negative": 13, "neutral": 25, "score": 46, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 7, "negative_events": 13}, "market_context": {"has_market_context": true, "latest_close": 2.53, "latest_week": "2026-07-17", "one_week_move": -3.8, "four_week_move": -35.1, "twelve_week_move": -23.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.237733, "market_dynamics_buy_signal": false, "relative_strength": -29.544408, "fair_value_gap": -91.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.9922, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.8% over one week, -35.1% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "Investing.com South Africa", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 4}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.8% over one week, -35.1% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026)"}], "updated_at": "2026-07-20T23:55:21.559722+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}